about
Interaction of tumor cells with the microenvironmentβ1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomaIrradiation-induced up-regulation of HLA-E on macrovascular endothelial cells confers protection against killing by activated natural killer cellsThe vascular basement membrane as "soil" in brain metastasisNovel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cellsβ₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyHuman breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancerHigh threshold of β1 integrin inhibition required to block collagen I-induced membrane type-1 matrix metalloproteinase (MT1-MMP) activation of matrix metalloproteinase 2 (MMP-2)Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapyBreast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase.β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin β1 and migration in colon cancer cells.Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapyMolecular targets for tumor radiosensitization.Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway.Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents.Integrins in lens development and disease.beta1 integrin targeting to enhance radiation therapy.Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer.Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability.Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology.The cancer cell adhesion resistome: mechanisms, targeting and translational approaches.Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.Imaging the inhibition by anti-β1 integrin antibody of lung seeding of single osteosarcoma cells in live mice.β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.Association between polymorphisms of microRNA-binding sites in integrin genes and gastric cancer in Chinese Han population.Effects of N-acetyl-L-cysteine on adhesive strength between breast cancer cell and extracellular matrix proteins after ionizing radiation.Extracellular Matrix and Integrin Expression Profiles in Fuchs Endothelial Corneal Dystrophy Cells and Tissue Model.FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition.SPP1 promotes ovarian cancer progression via Integrin β1/FAK/AKT signaling pathway.Anti-Tumorigenic and Anti-Metastatic Activity of the Sponge-Derived Marine Drugs Aeroplysinin-1 and Isofistularin-3 against Pheochromocytoma In Vitro.Nanoscale imaging of the adhesion core including integrin β1 on intact living cells using scanning electron-assisted dielectric-impedance microscopy
P2860
Q21245506-4408F744-A868-4FAA-9CEF-C753670F053DQ24564890-5D39DE30-8DB3-4EE7-A4CF-1D9EF2B53E67Q27312526-4322B915-3C5D-43BC-98F9-90DF6CA66AAEQ27348725-D115A135-C487-44FD-BFF0-B73C5EA321F3Q28829821-80016787-A246-46F5-BB98-473AAEAB425AQ30427521-ABB57DA7-CEED-4830-ABB8-03A29EF90D66Q30666838-6EC7BE35-8C6F-4AA6-9DB9-3438B21A1820Q33590428-2007B753-ADC1-49B7-ADBD-6E79015E9B93Q34332877-0A4FEB01-1991-4246-9A02-6A59D5CC74C9Q35014893-64919392-4F81-4BCE-B9AC-79736938E945Q35558971-D734E597-DDBF-47EE-AD0E-AD78FDAA2F93Q35608736-34E838D5-7E89-4E98-B6FA-B28FCFEEBE37Q35955468-6E2E8060-E38C-4578-AA36-513D3C5E87EEQ36065096-8E0D0D03-9B18-49C1-A874-7BF610249F6FQ36126009-6BDD6D54-E91A-4CDE-B625-65F0519B6985Q36592509-A5A27612-B846-49CB-AC31-8E18887DA170Q36870047-AEE441BC-5B25-4C8B-9757-DC3169D4173CQ37232153-18ABC333-7C74-402F-8EB0-A25AB1815F05Q37628720-26AAD833-EDCD-489C-97DE-E0B56BC5B0AAQ38169157-0E845143-44C6-4424-8F4C-031AB3648949Q38224260-D5F4E201-9F3E-4EC2-A3B0-CE9D33B1FA7AQ38869424-964BB788-06B4-48A5-9789-3FA5E21E1F47Q39046463-78E2C6A5-B7B4-4487-88D3-443DB5BFE179Q39174318-33CA1DA5-B3D1-45F8-B185-3C0FF1C96E58Q39398473-089CD521-86E5-4837-87EF-2ECC82973FD8Q39561498-2F652D48-EAE0-4AC1-8153-A4E73CC09BF6Q41729920-971AB0EE-BD5B-4598-BA61-211ACE051095Q41810598-69E2D886-14C6-440E-917B-ECD607FEF93DQ47904121-22213D14-258E-4274-AA79-2D2BC453C4BDQ51080131-306466B7-6A8C-483B-BA11-A03C03627938Q52579594-05F8084C-0006-467C-875C-FDE651A7D373Q53688963-833CEF28-47E1-4760-B036-A7A4AECF7364Q54120290-C851363A-6445-46B1-A9D6-93A6EE7425ABQ55331747-DA4FAA82-0FE1-4CD7-9A42-8D0E082C4F4FQ57120109-7282A5D5-F6EF-4516-84C8-282D1D17503C
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
beta1 integrin as a molecular therapeutic target.
@en
beta1 integrin as a molecular therapeutic target.
@nl
type
label
beta1 integrin as a molecular therapeutic target.
@en
beta1 integrin as a molecular therapeutic target.
@nl
prefLabel
beta1 integrin as a molecular therapeutic target.
@en
beta1 integrin as a molecular therapeutic target.
@nl
P2860
P1476
beta1 integrin as a molecular therapeutic target
@en
P2093
Catherine C Park
P2860
P304
P356
10.1080/09553000701639694
P50
P577
2007-11-01T00:00:00Z